Cent Eur J Public Health 2017, 25(1):3-10 | DOI: 10.21101/cejph.a4717

Prevalence and Risk Factors of Osteoporosis in Postmenopausal Women with Type 2 Diabetes Mellitus

Ivan Raška Jr., Mária Rašková, Vít Zikán, Jan Škrha
Third Department of Medicine - Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

Objective: Patients with type 2 diabetes (T2DM) are at increased risk of fractures. The aim of this study is to analyze the prevalence and risk factors of osteoporosis and osteoporosis related fractures in postmenopausal women with T2DM.

Methods: A total of 112 postmenopausal women with T2DM and 171 control nondiabetic women received a standardized questionnaire on osteoporosis risk factors, and were evaluated for bone mineral density (BMD, by using a dual energy X-ray absorptiometry), biochemical markers of bone and glucose metabolism, soluble receptor for advanced glycation end products (sRAGE) and its gene polymorphisms (rs1800625 or rs2070600).

Results: In T2DM patients the prevalence of osteoporosis was 25% and low trauma vertebral (Vfx) and non-vertebral fractures were found in 8% and 19% women, respectively. When compared between subjects with and without fractures, there were no significant differences in BMD at any site between the groups, except for distal radius, which was significantly lower in T2DM women with Vfx (p<0.05 vs.non-fractured without osteoporosis). We found no associations between bone and glucose metabolism variables, sRAGE and BMD. No significant differences were observed in sRAGE levels according to their rs1800625, rs 2070600 genotype or fracture prevalence. Serum osteocalcin was significantly lower in T2DM women (p<0.01 vs. controls) and in T2DM women with Vfx (p<0.05) vs. non-fractured without osteoporosis. T2DM women with low daily walking activity (< 2 h daily) had significantly higher serum sclerostin levels (p<0.05 vs. those who were walking > 2 h daily).

Conclusion: Diabetes-specific parameters as well as RAGE polymorphisms did not associate with BMD or fractures in T2DM postmenopausal women. Lower levels of osteocalcin, namely in those with Vfx and higher sclerostin levels in those with low daily walking activity suggest lower bone remodeling and/or decreased bone quality in T2DM.

Keywords: type 2 diabetes mellitus, bone mineral density, osteoporosis, soluble RAGE, RAGE polymorphisms

Received: February 1, 2016; Revised: June 2, 2016; Accepted: June 2, 2016; Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Raška I, Rašková M, Zikán V, Škrha J. Prevalence and Risk Factors of Osteoporosis in Postmenopausal Women with Type 2 Diabetes Mellitus. Cent Eur J Public Health. 2017;25(1):3-10. doi: 10.21101/cejph.a4717. PubMed PMID: 28399348.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007 Sep 1;166(5):495-505. Go to original source... Go to PubMed...
    2. Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008 Aug;23(8):1334-42. Go to original source... Go to PubMed...
    3. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int. 2007 Apr;18(4):427-44. Go to original source... Go to PubMed...
    4. Yamaguchi T, Sugimoto T. Bone metabolism and fracture risk in type 2 diabetes mellitus. Bonekey Rep. 2012 Mar 7;1:36. doi: 10.1038/bonekey.2012.27. Go to original source... Go to PubMed...
    5. Gaens KH, Ferreira I, van der Kallen CJ, van Greevenbroek MM, Blaak EE, Feskens EJ, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab. 2009 Dec;94(12):5174-80. Go to original source... Go to PubMed...
    6. Yamamoto M,Yamaguchi T,Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009 Dec;32(12):2263-8. Go to original source... Go to PubMed...
    7. Sanguineti R, Puddu A, Mach F, Montecucco F, Viviani GL. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm. 2014;2014:975872. doi: 10.1155/2014/975872. Go to original source... Go to PubMed...
    8. Oz SG, Guven GS, Kilicarslan A, Calik N, Beyazit Y, Sozen T. Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl Med Assoc. 2006 Oct;98(10):1598-604. Go to PubMed...
    9. Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients - a metaanalysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014 Jun;25(6):1697-708. Go to original source... Go to PubMed...
    10. Liu C, Wo J, Zhao Q, Wang Y, Wang B, Zhao W. Association between serum total osteocalcin level and type 2 diabetes mellitus: a systematic review and meta-analysis. Horm Metab Res. 2015 Oct;47(11):813-9. Go to original source... Go to PubMed...
    11. Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008 Dec;19(12):1683-704. Go to original source...
    12. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/ beta-catenin signaling. J Bone Miner Res. 2009 Oct;24(10):1651-61. Go to original source... Go to PubMed...
    13. Zhou YJ, Li A, Song YL, Zhou H, Li Y, Tang YS. Role of sclerostin in the bone loss of postmenopausal chinese women with type 2 diabetes. Chin Med Sci J. 2013 Sep;28(3):135-9. Go to original source... Go to PubMed...
    14. Hernandez RK, Do TP, Critchlow CW, Dent RE, Jick SS. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop. 2012 Dec;83(6):65360. Go to original source... Go to PubMed...
    15. Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider JG. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2014 Apr 11;14:33. doi: 10.1186/1472-6823-14-33. Go to original source... Go to PubMed...
    16. Viégas M, Costa C, Lopes A, Griz L, Medeiro MA, Bandeira F. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications. 2011 JulAug;25(4):216-21. Go to original source... Go to PubMed...
    17. Khosla S, Atkinson EJ, Riggs BL, Melton LJ 3rd. Relationship between body composition and bone mass in women. J Bone Miner Res. 1996 Jun;11(6):857-63. Go to original source... Go to PubMed...
    18. Nielson CM, Marshall LM, Adams AL, LeBlanc ES, Cawthon PM, Ensrud K, et al.; Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J Bone Miner Res. 2011 Mar;26(3):496-502. Go to original source... Go to PubMed...
    19. Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013 Feb;28(2):313-24. Go to original source... Go to PubMed...
    20. Samelson E, Bouxsein M, Brochin E, Zhang XC, Meng CA, Broe K, et al. Deficits in cortical bone density and microstructure in type 2 diabetes: Framingham HR-pQCT Study. J Bone Miner Res. 2014 Feb;29 Suppl 1:S28.
    21. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc NatlAcad Sci U SA. 2008 Apr 1;105(13):5266-70. Go to original source... Go to PubMed...
    22. Kanazawa I,Yamaguchi T,Yamauchi M,Yamamoto M, Kurioka S,Yano S, et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int. 2011 Jan;22(1):187-94. Go to original source... Go to PubMed...
    23. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 Jan;97(1):234-41. Go to original source... Go to PubMed...
    24. Cohen A, Dempster DW, Recker RR, Lappe JM, Zhou H, Zwahlen A, et al. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab. 2013 Jun;98(6):2562-72. Go to original source... Go to PubMed...
    25. Alselami NM, Noureldeen AF, Al-Ghamdi MA, Khan JA, Moselhy SS. Bone turnover biomarkers in obese postmenopausal Saudi women with type-II diabetes mellitus. Afr Health Sci. 2015 Mar;15(1):90-6. Go to original source... Go to PubMed...
    26. Achemlal L, Tellal S, Rkiouak F, Nouijai A, Bezza A, Derouiche el M, et al. Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol. 2005 Sep;24(5):493-6. Go to original source... Go to PubMed...
    27. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005 Dec;16(12):1506-12. Go to original source... Go to PubMed...
    28. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res. 2005 Sep;20(9):1647-58. Go to original source... Go to PubMed...
    29. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab. 2000 Nov;11(9):368-75. Go to original source...
    30. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011 Dec;12(14):2096-102. Go to original source... Go to PubMed...
    31. Motawi TM, Abou-Seif MA, Bader AM, Mahmoud MO. Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients. BMC Endocr Disord. 2013 Aug 21;13:32. doi: 10.1186/14726823-13-32. Go to original source... Go to PubMed...
    32. Ardawi MS,Akhbar DH,AlshaikhA,Ahmed MM, Qari MH, RouziAA, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013 Oct;56(2):355-62. Go to original source... Go to PubMed...
    33. Raška I Jr., Týblová M, Rašková M, Michalská D, Havrdová E, Zikán V. Limited walking ability significantly contributes to a loss of bone mineral density in the proximal femur in premenopausal and postmenopausal women with multiple sclerosis. Osteol Bull. 2012;17(4):128-135. (In Czech.)
    34. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA. 2002 Nov 13;288(18):2300-6. Go to original source... Go to PubMed...
    35. Lee RH, Pieper CF, Colón-Emeric C. Functional Impairments Mediate Association Between Clinical Fracture Risk and Type 2 Diabetes Mellitus in Older Women. J Am Geriatr Soc. 2015 Aug;63(8):1546-51. Go to original source... Go to PubMed...

    Return to the content